Chemed Quarterly Income Statement
NYSE: CHEHealth CareMedical/Nursing ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Chemed revenue and earnings
In the quarter ended Jun 30, 2026, Chemed generated $673.3 million in revenue, up 8.8% from the same quarter a year earlier. Net income was $67.7 million (+29.0% year over year), for a net margin of 10.1% versus a median of 10.3% in the prior 5 quarters. Gross margin was 32.9% (up from 29.8%) and operating margin 13.2%.
Diluted earnings per share came in at $5.13, up from $3.57.
Summary generated from market data by MetaCap's automated system. Methodology
Chemed income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.25M | 657.51M | 639.34M | 624.90M | 618.80M | 646.94M | 639.99M | 606.18M | 595.88M | 589.23M | 585.91M | 564.53M |
| Revenue growth (YoY) | +8.80% | +1.63% | -0.10% | +3.09% | +3.85% | +9.79% | +9.23% | +7.38% | +7.60% | +5.19% | +7.18% | +7.23% |
| Cost of Revenue | 451.78M | 441.75M | 414.17M | 427.99M | 434.11M | 430.53M | 405.88M | 396.19M | 389.75M | 385.13M | 358.35M | 362.36M |
| Gross Profit | 221.47M | 215.76M | 225.17M | 196.91M | 184.69M | 216.41M | 234.12M | 209.99M | 206.13M | 204.11M | 227.57M | 202.17M |
| Operating Expenses | 584.05M | 572.93M | 538.68M | 550.15M | 550.71M | 552.18M | 526.12M | 514.02M | 507.75M | 516.90M | 116.17M | 115.32M |
| Selling, General & Admin | 115.20M | 114.32M | 105.50M | 105.78M | 100.32M | 105.59M | 104.25M | 101.98M | 102.25M | 115.87M | 100.44M | 99.60M |
| Operating Income | 89.20M | 84.58M | 100.65M | 74.75M | 68.08M | 94.76M | 113.88M | 92.16M | 88.13M | 72.33M | 111.39M | 86.85M |
| Interest Expense | 1.79M | 512.00K | 521.00K | 457.00K | 443.00K | 329.00K | 499.00K | 427.00K | 429.00K | 425.00K | 342.00K | 444.00K |
| Other Income (Expense) | 3.91M | 4.77M | 5.31M | 9.25M | 3.47M | 1.25M | 6.74M | 9.30M | 6.13M | 12.58M | 4.54M | 6.86M |
| Pretax Income | 91.33M | 88.84M | 105.44M | 83.54M | 71.11M | 95.67M | 120.12M | 101.03M | 93.83M | 84.48M | 115.59M | 93.27M |
| Income Tax | 23.63M | 22.54M | 28.69M | 19.31M | 18.62M | 23.92M | 29.80M | 25.25M | 22.94M | 19.47M | 25.54M | 18.31M |
| Net Income | 67.70M | 66.30M | 76.75M | 64.24M | 52.49M | 71.76M | 90.32M | 75.78M | 70.89M | 65.02M | 90.05M | 74.96M |
| Net Income growth (YoY) | +28.98% | -7.60% | -15.02% | -15.23% | -25.95% | +10.37% | +0.30% | +1.09% | +32.80% | +20.13% | +44.95% | +31.80% |
| EPS (Basic) | 5.14 | 4.85 | 5.45 | 4.46 | 3.60 | 4.91 | 6.06 | 5.04 | 4.70 | 4.30 | 5.98 | 4.97 |
| EPS (Diluted) | 5.13 | 4.84 | 5.45 | 4.46 | 3.57 | 4.86 | 6.00 | 5.00 | 4.65 | 4.24 | 5.91 | 4.93 |
| Shares Outstanding (Basic) | 13.17M | 13.68M | — | 14.39M | 14.59M | 14.62M | — | 15.03M | 15.10M | 15.12M | — | 15.07M |
| Shares Outstanding (Diluted) | 13.20M | 13.69M | — | 14.41M | 14.70M | 14.76M | — | 15.17M | 15.25M | 15.34M | — | 15.20M |
| EBITDA | 106.19M | 101.45M | 116.98M | 90.98M | 84.34M | 110.78M | 129.71M | 107.85M | 103.84M | 88.14M | 126.93M | 102.23M |
| Gross Margin | 32.90% | 32.82% | 35.22% | 31.51% | 29.85% | 33.45% | 36.58% | 34.64% | 34.59% | 34.64% | 38.84% | 35.81% |
| Operating Margin | 13.25% | 12.86% | 15.74% | 11.96% | 11.00% | 14.65% | 17.79% | 15.20% | 14.79% | 12.28% | 19.01% | 15.38% |
| Net Margin | 10.06% | 10.08% | 12.00% | 10.28% | 8.48% | 11.09% | 14.11% | 12.50% | 11.90% | 11.03% | 15.37% | 13.28% |
This table shows 12 quarterly periods of Chemed's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CHE's reporting calendar. What is a income statement?